Last edition
News about
Roche Reports Update on PERSEVERA Breast Cancer Trial
Roche reported that the Phase III persevERA study in ER-positive advanced breast cancer did not meet its primary endpoint, though giredestrant plus palbociclib showed numerical improvement and a tolerable safety profile.
TaiGen Biotechnology doses first participant in Phase I trial of ISM4808, an AI-designed oral therapy from Insilico Medicine for chronic kidney disease-related anemia.
Hopewell Therapeutics and Foxcroft Therapeutics partner to advance cancer vaccines using tissue-targeting lipid nanoparticles, enabling improved delivery systems with large-animal trials planned later in 2026.
Dyne Therapeutics Reports Positive Results from Z-Rostudirsen DMD Study
Dyne Therapeutics reported new 24-month data from the DELIVER trial showing Z-rostudirsen improved cardiopulmonary function in patients with Duchenne Muscular Dystrophy (DMD), building on earlier findings of sustained functional benefits across multiple clinical measures.
Cipla USA Recalls Cancer Drug Batches Over Manufacturing Issue
The recall involves Nilotinib capsules in two strengths—150 mg and 200 mg—distributed in the US market. The affected batches include a total of 435 cartons, comprising 271 cartons from one lot and 164 from another.
Sanofi Board Nominates Christel Heydemann as Independent Director
Sanofi has nominated Christel Heydemann as an Independent Director, subject to shareholder approval at its AGM on 29 April. The company also announced that Patrick Kron, Independent Director and Chairman of the Nomination, Governance and CSR Committee, will step down at the end of his term.
Biologos Appoints Hetal Patel as Chief Executive Officer
Biologos, a leading ISO 13485–certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions, announced the appointment of Hetal Patel as chief executive officer.
Servier Strikes USD 2.5 Billion Deal to Buy Day One Biopharmaceuticals
French drugmaker Servier has agreed to acquire US-based Day One Biopharmaceuticals in an all-cash deal valued at approximately USD 2.5 billion, as the company seeks to strengthen its presence in rare oncology and brain tumour therapies.
UK Space Agency Launches Initiative to Accelerate Development of Space-Manufactured Medicines
UK Space Agency, with Medicines and Healthcare products Regulatory Agency and partners, unveils regulatory support and innovation programmes to help companies develop microgravity-manufactured medicines and bring them from orbit to patients.
GAIA AG and Daiichi Sankyo Europe form an exclusive partnership to commercialise lipodia, a digital therapeutic designed to help adults with Hypercholesterolemia adopt sustainable lifestyle changes for improved cardiovascular health.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy